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Abstract
Aims/hypothesis We aimed to investigate the risk of cancer
mortality in relation to the glucose tolerance status
classified according to the 2 h OGTT.
Methods Data from 17 European population-based or occupa-
tional cohorts involved in the DECODE study comprising
26,460 men and 18,195 women aged 25–90 years were
collaboratively analysed. The cohorts were recruited between
1966 and 2004 and followed for 5.9 to 36.8 years. Cox
proportional hazards analysis with adjustment for cohort, age,
BMI, total cholesterol, blood pressure and smoking status was
used to estimate HRs for cancer mortality.
Results Compared with people in the normal glucose category,
multivariable adjusted HRs (95% CI) for cancer mortality were
1.13 (1.00, 1.28), 1.27 (1.02, 1.57) and 1.71 (1.35, 2.17) in men
with prediabetes, previously undiagnosed diabetes and known
diabetes, respectively; in women they were 1.11 (0.94, 1.30),
1.31 (1.00, 1.70) and 1.43 (1.01, 2.02), respectively. Significant
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increases in deaths from cancer of the stomach, colon–
rectum and liver in men with prediabetes and diabetes, and
deaths from cancers of the liver and pancreas in women
with diabetes were also observed. In individuals without
known diabetes, the HR (95% CI) for cancer mortality
corresponding to a one standard deviation increase in fasting
plasma glucose was 1.06 (1.02, 1.09) and in 2 h plasma
glucose was 1.07 (1.03, 1.11).
Conclusions/interpretation Diabetes and prediabetes were
associated with an increased risk of cancer death, particu-
larly death from liver cancer. Mortality from all cancers
rose linearly with increasing glucose concentrations.
Keywords Cancer . Diabetes . Mortality
Abbreviations
2-hPG 2 h Plasma glucose
DECODE Diabetes Epidemiology: Collaborative analysis
Of Diagnostic criteria in Europe
FPG Fasting plasma glucose
MPP Malmö Preventive Project
NGT Normal glucose tolerance
NHANES National Health and Nutrition Examination
Survey
Introduction
Epidemiological studies have shown that diabetes [1–7] or
certain treatments for diabetes may increase the risk [8–10] of
developing cancer. Diabetes may also affect the treatment of
cancer; some types of cancer are treated less aggressively in
patients with diabetes than in patients without diabetes [11].
Evidence for the association between diabetes and cancer-
related mortality is, however, still limited and results from
different studies are controversial. It was reported that diabetic
patients suffered from higher mortality rates from all cancers
[12] or some types of cancers [13, 14] than the general
population. Pre-existing diabetes was a risk factor for all-
cancer death in Japanese women [15] and for death from
some types of cancers in a US population [16]. No association
between diabetes and all-cancer mortality was found in an
occupational male group (Whitehall study) in the UK [17] or
in the Second National Health and Nutrition Examination
Survey (NHANES II) Mortality Study in the USA [18]. The
NHANES II has, however, found IGT to be associated with a
higher risk of cancer mortality. Cancer mortality may also
increase with increasing fasting [19, 20], non-fasting [20] or
postload [21] glucose levels.
The aim of this study was to investigate the risk of
cancer mortality in relation to the glucose tolerance status
based on data from the Diabetes Epidemiology: Collabora-
tive analysis of Diagnostic criteria in Europe (DECODE)
Study.
Methods
The study populations and the methods used to recruit
participants for the DECODE study have been reported
previously [22, 23]. In brief, researchers in Europe who had
performed population-based studies or large studies in
occupational groups using the standard 2 h 75 g OGTT
were invited to participate in the DECODE study. In the
current study, 15,631 participants (12,999 men and 2,632
women) from the Malmö Preventive Project (MPP,
Sweden) who underwent 2 h OGTT using 30 g oral
glucose load per body surface area (m2) [24] were also
included. Individual data from each study cohort were
sent to the Diabetes Prevention Unit of the National
Institute for Health and Welfare in Helsinki, Finland, for
data analyses. Each study was approved by the local
ethics committees and the analysis plan was approved by
the ethics committee of the National Institute for Health
and Welfare.
A total of 44,655 participants from 17 study cohorts with
prospective data on cause-specific mortality and all other
required variables of fasting plasma glucose (FPG), 2 h plasma
glucose (2-hPG) after a glucose load, BMI, total serum
cholesterol, blood pressure and smoking status were included
in the current data analyses. All 17 study cohorts included men
(n=26,460) and 14 also included women (n=18,195). The
baseline age of the participants ranged from 25 to 90 years
with mean ages varying from 45 to 76 years in different study
cohorts. The study cohorts were recruited between 1966 and
2004 and followed up for 5.9 to 36.8 years, with median
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(25th, 75th percentile) follow up of 15.8 years (9.1, 23.2 years)
in all cohorts combined (Table 1). Men contributed 467,872
person-years and women contributed 252,503 person-years of
follow up. Informed consent was obtained from all partic-
ipants in each study.
In the current study population, participants who had a
prior history of diabetes or who were on antihypergly-
caemic treatment before the baseline survey were
considered as having known diabetes. Participants with-
out known diabetes at the baseline survey were classified
according to the World Health Organization definition
[25]. Undiagnosed diabetes is defined as having either FPG ≥
7.0 mmol/l and/or 2-hPG ≥ 11.1 mmol/l. IGT is defined as
having FPG < 7.0 mmol/l and 2-hPG ≥ 7.8 mmol/l but
<11.1 mmol/l. IFG is defined as having FPG ≥ 6.1 mmol/l but
<7.0 mmol/l and 2-hPG < 7.8 mmol/l. NGT is defined as FPG
< 6.1 mmol/l and 2-hPG < 7.8 mmol/l. People with IGTand/or
IFG were labelled as having ‘prediabetes’.
Vital status and the cause of death were obtained from
national cause-of-death registers or from medical records if the
register was not available in some countries for each participant
in all studies. Participants who emigrated, for whom the vital
status could not be confirmed, were considered as censored
cases. Cancer death was defined by the International Classifi-
cation of Disease codes 140-207 and 209 (8th revision), codes
140-208 (9th revision) and codes C00-C97 (10th revision). No
data on autopsy was provided.
Statistical methods Statistical analysis was performed using
the SPSS for Windows version 15.0 (SPSS Inc, Chicago,
IL, USA) and STATA version 9.2 (StataCorp, College
Station, TX, USA). Means and differences in means
between groups were estimated using univariate general
linear models with adjustments for age and study for
continuous variables. χ2 test was used to test differences in
proportions between groups. Crude mortality rates per
1,000 person-years were calculated for each glucose
tolerance category. HRs and their 95% CIs for cancer death
were estimated using a Cox proportional hazards model for
different glucose intolerance groups at the presence of
Table 1 Mean (±SD) age at baseline and number (%) of cancer deaths during the follow-up in each study cohort
Study cohort Men
(n)
Women
(n)
Age
(years)
Cancer deaths (n) Maximum follow-up
(years)
Men Women
Denmark
Glostrup [35] 1,050 1,029 52.1±12.2 109 (10.4) 88 (8.6) 27.0
Finland
East–West Finlanda [36] 405 – 76.2±4.5 70 (17.3) – 17.1
FINRISK-1987 [37] 1,261 1,440 54.0±5.7 119 (9.4) 90 (6.3) 20.9
FINRISK-1992 [37] 877 1,041 54.1±6.0 44 (5.0) 53 (5.1) 16.0
FINRISK-2002 [38] 1,786 2,055 57.9±7.8 35 (2.0) 18 (0.9) 5.9
Helsinki policemena [39] 1,136 – 44.7±8.0 175 (15.4) – 36.8
Oulu [40] 418 603 60.9±9.7 21 (5.0) 12 (2.0) 15.0
Vantaa [41] 271 335 65.1±0.4 22 (8.1) 19 (5.7) 17.9
Italy
Cremona [42] 800 999 58.4±10.8 102 (12.8) 63 (6.3) 15.7
The Netherlands
Hoorn [43] 1,116 1,317 61.6±7.3 62 (5.6) 52 (3.9) 10.2
Poland
Krakow [44] 163 186 57.8±8.3 3 (1.8) 3 (1.6) 6.6
Sweden
Northern Sweden MONICA Survey [45] 1,733 1,760 48.9±13.4 42 (2.4) 33 (1.9) 20.6
Malmö (MPP) [24] 12,999 5,881 49.6±4.9 1,381 (10.6) 367 (6.2) 30.3
Uppsalaa [46] 1,164 – 71.0±0.6 123 (10.6) – 12.4
UK
Cambridge (Ely) [47] 435 607 54.0±7.8 19 (4.4) 30 (4.9) 15.7
Goodinge [48] 448 566 54.6±10.3 19 (4.2) 27 (4.8) 9.7
Newcastle [49] 398 376 54.8±12.5 19 (4.8) 15 (4.0) 10.6
Total 26,460 18,195 53.4±9.5 2,365 (8.9) 870 (4.8) 36.8
a The cohort includes only men
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covariates of study cohort, age at baseline (years), BMI (kg/m2),
systolic blood pressure (mmHg), serum cholesterol (mmol/l)
and smoking status. Stratified analysis by the BMI tertiles was
also made for different glucose intolerance groups adjusting for
study cohort, age, sex, systolic blood pressure, serum
cholesterol and smoking status. Fasting insulin was analysed
in only a subgroup of men (n=15,227) and women (n=9,221)
who had fasting insulin measured at baseline survey. Time
since baseline was used as the time-scale in the Cox
proportional hazards model. Interaction between the glucose
intolerance and smoking status was examined to evaluate
whether the effect of glucose intolerance on cancer mortality
differed in smokers from that in non-smokers.
The HRs (95% CIs) for cancer death corresponding to a
study-specific one standard deviation (SD) increase in linear
form of the FPG and 2-hPG in individuals without a prior
history of diabetes were also estimated for each study adjusting
for age, sex, BMI, systolic blood pressure, cholesterol and
smoking status. Heterogeneity between studies was assessed
using Cochran’sQ statistics and I2 statistics, a transformation
of Q that estimates the percentage of total variation across
studies that is due to heterogeneity [26]. An overall HR for
all studies combined was then calculated using the Mantel–
Haenszel method for a fixed-effect model. The influence of
individual studies on the overall estimate was assessed by
calculating pooled HRs while omitting one study at a time.
Results
Individuals who died from cancer were older, less obese and
comprised a higher proportion of current smokers than others
(Table 2). A total of 2,365 cancer deaths were documented in
men during a median follow-up of 18.0 years and 870 cancer
deaths were recorded in women during 14.9 years. Age-
standardised all-cancer mortality rate was higher in individ-
uals with diabetes than in those without in both sexes
(Table 3).
Compared with NGT, the multivariable-adjusted HRs
(95% CI) for all-cancer death increased with worsening
glucose intolerance status; they were 1.13 (1.00, 1.28) for
prediabetes, 1.27 (1.02, 1.57) for previously undiagnosed
diabetes and 1.71 (1.35, 2.17) for known diabetes in men. The
results were similar in women (Table 3). The multivariable-
adjusted HR for site-specific cancer death was estimated
when more than 90 events accumulated in a cancer
subgroup. Certain types of site-specific cancers were
combined in the final data analyses because of the low
numbers in each group. Compared with individuals with
NGT, the HR was higher for death from cancers in stomach,
colon–rectum and liver in men with prediabetes and diabetes,
and for deaths from cancers in liver and pancreas in women;
however, this increase was only of borderline significance in
women with prediabetes and undiagnosed diabetes (Table 3).
The interaction term between glucose intolerance and
smoking was not statistically significant, i.e. smoking did
not modify the effect of glucose intolerance on cancer.
The multivariable-adjusted HRs for all-cancer death was
also estimated within each BMI tertile. Compared with NGT,
the HRs (95% CIs) were 1.14 (0.96, 1.36) for prediabetes,
1.15 (0.76, 1.73) for previously undiagnosed diabetes and
1.58 (1.06, 2.35) for known diabetes in individuals in the
lowest tertile of BMI (<24.0 kg/m2); they were 1.27 (1.08,
1.50), 1.12 (0.79, 1.59) and 1.69 (1.16, 2.46) in the middle
Variable Cancer death in men Cancer death in women
No Yes No Yes
n (%) 24,095 (91.1) 2,365 (8.9) 17,325 (95.2) 870 (4.8)
Age (years) 52.0±0.1 54.2±0.2 a 54.9±0.1 57.4±0.3 a
BMI (kg/m2) 25.9±0.02 25.5±0.1 a 26.3±0.04 25.9±0.2 b
Blood pressure (mmHg)
Systolic 135±0.1 135±0.4 134±0.1 133±0.7 b
Diastolic 85±0.1 86±0.2 81±0.1 81±0.4
Cholesterol (mmol/l) 5.9±0.01 5.9±0.02 6.2±0.01 6.3±0.04a
Glucose tolerance status, n (%)
Normal glucose tolerance 18,169 (75.4) 1,817 (76.8) 10,879 (62.8) 518 (59.5)
Prediabetes 4,149 (17.2) 372 (15.7) 4,746 (27.4) 246 (28.3)
Undiagnosed diabetes 1,075 (4.5) 95 (4.0) 1,129 (6.5) 67 (7.7)
Known diabetes 702 (2.9) 81 (3.4) 571 (3.3) 39 (4.5)
Smoking status, n (%)
Current smoker 9,386 (39.0) 1,310 (55.4)a 4,208 (24.3) 314 (36.1)a
Ex-smoker 4,586 (19.0) 327 (13.8) 2,730 (15.8) 108 (12.4)
Table 2 Baseline characteris-
tics of men and women by
all-cancer death
Data are cohort-adjusted
and age-adjusted mean ± SE
or n (%)
Prediabetes included
impaired fasting glucose
and/or impaired glucose
tolerance
a p<0.001, b p<0.05 for the differ-
ence between groups with and
without cancer death
1870 Diabetologia (2010) 53:1867–1876
Table 3 Crude cancer mortality (per 1,000 person-years) and multivariable-adjusted HR in relation to glucose tolerance status in men and women
Type of cancer NGT Prediabetes Undiagnosed diabetes Known diabetes All diabetes
Men
All cancers
No. of deaths 1,817 372 95 81 176
Mortality 4.76 5.69 6.92 11.67 8.52
HR (95% CI)a 1.0 1.13 (1.00, 1.28) 1.27 (1.02, 1.57) 1.71 (1.35, 2.17) 1.44 (1.21, 1.70)
Stomach or colon–rectum
No. of deaths 258 70 19 17 36
Mortality 0.68 1.07 1.38 2.45 1.74
HR (95% CI)a 1.0 1.46 (1.09, 1.94) 1.69 (1.03, 2.76) 2.07 (1.21, 3.51) 1.84 (1.25, 2.71)
Liver
No. of deaths 42 17 6 9 15
Mortality 0.11 0.26 0.44 1.30 0.73
HR (95% CI) a 1.0 2.32 (1.25, 4.33) 3.61 (1.42, 9.19) 7.50 (3.21, 17.54) 5.16 (2.56, 10.41)
Pancreas
No. of deaths 138 24 9 7 16
Mortality 0.36 0.37 0.66 1.01 0.77
HR (95% CI) a 1.0 0.88 (0.56, 1.41) 1.52 (0.74, 3.12) 1.92 (0.85, 4.33) 1.67 (0.94, 2.97)
Bronchus and lung
No. of deaths 497 88 15 10 25
Mortality 1.30 1.35 1.09 1.44 1.21
HR (95% CI) a 1.0 1.14 (0.89, 1.46) 0.85 (0.50, 1.45) 0.93 (0.49, 1.78) 0.88 (0.58, 1.35)
Prostate
No. of deaths 209 52 14 13 27
Mortality 0.55 0.79 1.02 1.87 1.31
HR (95% CI) a 1.0 1.01 (0.73, 1.40) 1.09 (0.62, 1.93) 1.64 (0.90, 2.99) 1.30 (0.84, 2.01)
Kidney or bladder
No. of deaths 119 14 5 6 11
Mortality 0.31 0.21 0.36 0.86 0.53
HR (95% CI) a 1.0 0.59 (0.33, 1.05) 0.84 (0.33, 2.13) 1.93 (0.79, 4.71) 1.20 (0.61, 2.37)
Women
All cancers
No. of deaths 518 246 67 39 106
Mortality 3.17 3.63 4.42 6.60 5.04
HR (95% CI) a 1.0 1.11 (0.94, 1.30) 1.31 (1.00, 1.70) 1.43 (1.01, 2.02) 1.35 (1.08, 1.68)
Stomach or colon–rectum
No. of deaths 66 40 3 2 5
Mortality 0.40 0.59 0.20 0.34 0.24
HR (95% CI) a 1.0 1.52 (1.00, 2.31) 0.49 (0.15, 1.59) 0.46 (0.11, 1.93) 0.48 (0.19, 1.21)
Liver
No. of deaths 8 5 3 6 9
Mortality 0.05 0.07 0.20 1.02 0.43
HR (95% CI) a 1.0 1.58 (0.49, 5.09) 3.67 (0.89, 15.12) 10.87 (3.16, 37.39) 6.37 (2.18, 18.62)
Pancreas
No. of deaths 47 21 7 6 13
Mortality 0.29 0.31 0.46 1.02 0.62
HR (95% CI) a 1.0 1.08 (0.63, 1.85) 1.71 (0.74, 3.94) 3.13 (1.21, 8.08) 2.13 (1.09, 4.16)
Bronchus and lung
No. of deaths 81 38 8 3 11
Mortality 0.50 0.56 0.53 0.51 0.52
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tertile (BMI 24.0–27.1 kg/m2) and 0.99 (0.85, 1.16), 1.36
(1.09, 1.69) and 1.51 (1.14, 2.00) in the upper tertile of the
BMI distribution (BMI ≥ 27.2 kg/m2). The risk of all-cancer
deaths therefore increased in individuals with diabetes
irrespective of their BMI levels.
After adding fasting insulin into the multivariable model
in a subgroup of individuals, we obtained HRs (95% CIs)
of 1.18 (1.02, 1.38), 1.34 (1.04, 1.74) and 1.52 (1.09, 2.12)
in men with prediabetes, undiagnosed and diagnosed
diabetes for all-cancer deaths; while these were 1.19
(1.03, 1.38), 1.36 (1.05, 1.76) and 1.58 (1.14, 2.18),
respectively, when fasting insulin was not fitted in the
model. In women, these values were 1.20 (0.92, 1.56), 1.23
(0.79, 1.91) and 1.71 (1.00, 2.93) after addition of fasting
insulin and 1.21 (0.92, 1.58), 1.26 (0.81, 1.95) and 1.91
(1.13, 3.21) before adjusting for fasting insulin. The results
therefore did not change substantially after adding fasting
insulin into the multivariable model.
After excluding the cancer deaths that occurred within
5 years after the baseline examination, the HRs (95%
CIs) for all-cancer death were 1.10 (0.96, 1.26) for
prediabetes, 1.27 (0.99, 1.62) for previously undiagnosed
diabetes and 1.62 (1.21, 2.18) for known diabetes in
men; they were 1.03 (0.86, 1.24), 1.25 (0.92, 1.69) and
Table 3 (continued)
Type of cancer NGT Prediabetes Undiagnosed diabetes Known diabetes All diabetes
HR (95% CI) a 1.0 1.12 (0.75, 1.69) 1.03 (0.49, 2.19) 0.72 (0.21, 2.43) 0.93 (0.48, 1.81)
Breast
No. of deaths 68 42 12 5 17
Mortality 0.42 0.62 0.79 0.85 0.81
HR (95% CI) a 1.0 1.47 (0.97, 2.22) 1.76 (0.92, 3.35) 1.44 (0.55, 3.76) 1.65 (0.93, 2.93)
Kidney or bladder
No. of deaths 17 12 2 5 7
Mortality 0.10 0.18 0.13 0.85 0.33
HR (95% CI) a 1.0 1.46 (0.67, 3.21) 1.03 (0.23, 4.61) 3.62 (1.09, 11.97) 1.97 (0.75, 5.15)
Total
No. of deaths 2,335 618 162 120 282
Mortality 4.28 4.64 5.61 9.34 6.76
HR (95% CI) a 1.0 1.12 (1.02, 1.23) 1.28 (1.08, 1.51) 1.57 (1.29, 1.91) 1.38 (1.21, 1.58)
Stomach or colon–rectum
No. of deaths 324 110 22 19 41
Mortality 0.59 0.83 0.76 1.48 0.98
HR (95% CI) a 1.0 1.46 (1.15, 1.84) 1.24 (0.79, 1.94) 1.46 (0.89, 2.39) 1.33 (0.94, 1.89)
Liver
No. of deaths 50 22 9 15 24
Mortality 0.09 0.17 0.31 1.17 0.58
HR (95% CI) a 1.0 2.01 (1.17, 3.44) 3.51 (1.63, 7.55) 8.47 (4.25, 16.86) 5.38 (3.03, 9.53)
Pancreas
No. of deaths 185 45 16 13 29
Mortality 0.34 0.34 0.55 1.01 0.70
HR (95% CI) a 1.0 1.02 (0.72, 1.44) 1.67 (0.97, 2.85) 2.34 (1.27, 4.32) 1.90 (1.24, 2.93)
Bronchus and lung
No. of deaths 578 126 23 13 36
Mortality 1.06 0.95 0.80 1.01 0.86
HR (95% CI) a 1.0 1.11 (0.90, 1.37) 0.90 (0.58, 1.38) 0.87 (0.49, 1.54) 0.89 (0.62, 1.27)
Kidney or bladder
No. of deaths 136 26 7 11 18
Mortality 0.25 0.20 0.24 0.86 0.43
HR (95% CI)a 1.0 0.82 (0.52, 1.27) 0.90 (0.41, 1.98) 2.45 (1.23, 4.88) 1.44 (0.83, 2.47)
Prediabetes included impaired fasting glucose and/or impaired glucose tolerance
a Adjusted for study cohort, age, sex (when men and women are combined), BMI, systolic blood pressure, cholesterol and smoking status
NGT, normal glucose tolerance
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1.14 (0.73, 1.77) in women and 1.07 (0.96, 1.19), 1.25
(1.03, 1.51) and 1.39 (1.09, 1.77) when men and women
were combined.
The 17 studies were homogeneous with respect to the
effect of FPG and 2-hPG on all-cancer death in
individuals without known diabetes (Q=12.9 on 16 df,
I2=0.0%, p=0.68 for FPG and Q=17.0 on 16 df, I2=5.9%,
p=0.38 for 2-hPG). Multivariate-adjusted overall HRs
(95% CIs) for all-cancer death were 1.06 (1.02, 1.09) and
1.07 (1.03, 1.11) corresponding to a one SD increase in
FPG and 2-hPG, respectively (Figs 1 and 2). Leaving any
one study out from the data analyses did not substantially
Overall  (I2=0.0%, p=0.682)
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Fig. 1 HR (black circle) and
95% CI (horizontal line) of all-
cancer death corresponding to a
study-specific one SD increase
in fasting plasma glucose for
each study cohort and for all
cohorts pooled together. The
size of the square is proportional
to the percentage weight of
each study cohort
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change the pooled HR for either FPG or 2-hPG. Removing
the MPP study, which contributed to more than 40%
weight of the overall estimate, only slightly increased the
pooled HR for 2-hPG (from 1.07 [95% CI 1.03, 1.11] to
1.11 [1.06, 1.17]).
Discussion
In this collaborative study, we found that mortality from
certain types of cancers, particularly from liver cancer,
was significantly increased not only in diabetic but also
in prediabetic populations compared with people with
NGT. The risk increased with deterioration in glucose
intolerance status and was highest in people with known
diabetes. Cancer mortality also increased with increasing
FPG and 2-hPG concentrations.
It was reported that diabetes independently predicted all-
cancer mortality in women in a Japanese population [15];
and mortality from cancers of colon, liver, pancreas and
bladder in men and from cancers of colon, pancreas and
breast in women in a US population [16]. Notably, the
diagnosis of diabetes was based on self-report in these
studies, those without symptoms of diabetes were not
identified. The impact of previously undiagnosed diabetes
and prediabetes on cancer death was therefore not deter-
mined. OGTTs were performed in the Whitehall study in
the UK [17] and in the NHANES II Mortality Study in the
USA [18]; neither previously diagnosed nor undiagnosed
diabetes predicted cancer death in these studies, whereas
IGT did so in the NHANES II Study. The number of
patients with diabetes was, however, much lower in the
both studies compared with our study.
Several mechanisms may be involved in the relation-
ship between glucose intolerance and the risk of cancer
mortality. Oxidative stress and accumulated advanced
glycation end-products induced by hyperglycaemia at the
cellular level may play important roles in cancer
development and progression [27]. Hyperinsulinaemia
and increased level of bioavailable insulin-like growth
factor I related to insulin resistance [28] may promote
cancer cell proliferation [29] and may also relate to worse
cancer outcome [29]. In our study, adjustment for fasting
insulin did not alter the relationship between glucose
intolerance and all-cancer death. Treatment choices for
cancer patients with diabetes may be limited by the
presence of hyperglycaemia and co-existing diabetes
complications [30] and certain types of cancer may be
treated less aggressively in patients with diabetes as a co-
morbidity than in patients without diabetes [11], which
may also lead to the worse cancer survival in patients with
diabetes. Although certain glucose-lowering agents have
been reported to increase the risk of cancer incidence [10]
and cancer mortality [31], the overall effect of glucose-
lowering treatments on cancer mortality in our study
population is unclear because the information on treatment
was not available in detail.
The collaborative data analysis with a relatively large
number of all-cancer death events accumulated increased
statistical power, and enabled data analysis for site-specific
cancers in subgroups. The effect of glucose intolerance on
cancer mortality was homogeneous across studies. Diabetes
was classified based on a standard 2 h 75 g OGTT, which
was not available in similar studies previously reported.
There were, however, several limitations with the data.
First, the date of cancer diagnosis was not documented; the
actual onset of prediabetes and undiagnosed diabetes was
also not known in one cross-sectional survey; as a result,
the direction of a causative relationship, if any, between
glucose intolerance and certain types of cancer such as
cancer of the pancreas cannot be determined. Second, the
duration of known diabetes, data on detailed treatments for
diabetic patients at baseline and during follow-up were not
available; the effect of glucose-lowering agents on the risk
of cancer death cannot be estimated. Third, alcohol
consumption and history of hepatitis and cirrhosis were
not recorded in the present study, which might confound
the effect of glucose intolerance on risk of death from liver
cancer. Dietary factors and physical activity were also
potential confounders but not available in this study.
Fourth, HbA1c was not determined and individuals who
met only HbA1c criteria for diabetes [32] might have been
misclassified as prediabetes or NGT [33, 34], which might
have obscured the relationship between diabetes and cancer
mortality. This needs to be further investigated.
In conclusion, the present study confirmed that diabetes
and prediabetes are independent risk predictors for all-
cancer death, particularly death from liver cancer. In
individuals without known diabetes, FPG and 2-hPG
concentrations are positively related to the risk of all-
cancer death.
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